We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

52 hedge funds and large institutions have $213M invested in Poseida Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
52
Holders Change
+52
Holders Change %
–
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
52
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$106M
2
PCM
Pentwater Capital Management
Florida
+$55.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$15.4M
4
BC
Boxer Capital
California
+$14.2M
5
SAM
Sectoral Asset Management
Quebec, Canada
+$12M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$76.9M +$106M +9,272,926 New
PCM
2
Pentwater Capital Management
Florida
$43.3M +$55.5M +4,879,490 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$12M +$15.4M +1,350,268 New
BC
4
Boxer Capital
California
$11.1M +$14.2M +1,251,055 New
SAM
5
Sectoral Asset Management
Quebec, Canada
$9.35M +$12M +1,053,779 New
ACM
6
Aisling Capital Management
New York
$9.25M +$11.9M +1,043,267 New
BlackRock
7
BlackRock
New York
$8.47M +$10.9M +955,255 New
VC
8
Vivo Capital
California
$8.22M +$10.5M +926,449 New
PA
9
Perceptive Advisors
New York
$6.99M +$8.96M +787,745 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$5.03M +$6.45M +566,951 New
RSCM
11
Rock Springs Capital Management
Maryland
$3.26M +$4.18M +367,499 New
VOYA Investment Management
12
VOYA Investment Management
Georgia
$2.46M +$3.15M +276,976 New
UBS AM
13
UBS AM
Illinois
$2.46M +$3.15M +277,071 New
IC
14
Ikarian Capital
Texas
$2.02M +$2.59M +228,000 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.68M +$2.15M +188,840 New
Northern Trust
16
Northern Trust
Illinois
$1.49M +$1.91M +167,550 New
PVI
17
Pura Vida Investments
New York
$1.32M +$1.69M +148,949 New
State Street
18
State Street
Massachusetts
$1.17M +$1.5M +131,648 New
UBS Group
19
UBS Group
Switzerland
$941K +$1.21M +106,085 New
Charles Schwab
20
Charles Schwab
California
$781K +$1M +87,978 New
SCM
21
Suvretta Capital Management
New York
$710K +$910K +80,000 New
SFI
22
Susquehanna Fundamental Investments
Pennsylvania
$587K +$753K +66,136 New
SSA
23
Schonfeld Strategic Advisors
New York
$434K +$557K +48,970 New
MA
24
MCF Advisors
Kentucky
$407K +$522K +45,833 New
Citadel Advisors
25
Citadel Advisors
Florida
$395K +$507K +44,515 New
1
2 3

PSTX Hedge Fund Activity: Q3 2020 in Review

52 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2020, worth a combined $213M.

Buyers outnumbered sellers: 52 funds opened new PSTX positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $106M.

  • 52 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $213M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2020.
  • 52 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2020 and 0 closed out, a net change of +52 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2020 was Fidelity Investments, an estimated $106M added.

Based on aggregated 13F filings for Q3 2020.